BackNavidea Biopharmaceuticals Overview

Navidea Biopharmaceuticals Receivables

Latest receivables for NAVB: $31K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$30870.00
80.11% YoYΔ $-124319.00 vs prior year quarter

Peer trimmed avg / median

Loading

Navidea Biopharmaceuticals Receivables History

Loading

Navidea Biopharmaceuticals vs. peers: Receivables Comparison

Loading

Navidea Biopharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Navidea Biopharmaceuticals (NAVB) FAQ

As of the most recent data (September 2023), NAVB shows a receivables of $31K. That compares with $160K in the prior-year period — down 80.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NAVB's receivables is now $31K (was $160K) — a 80.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Navidea Biopharmaceuticals is outperforming or lagging.

Tracking NAVB's receivables over time shows whether Navidea Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $31K That compares with $160K in the prior-year period — down 80.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Navidea Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $31K) with ownership activity and broader fundamentals.

Navidea Biopharmaceuticals's receivables is $31K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.